



Universiteit  
Leiden  
The Netherlands

## **The relationship between coronary calcification and the natural history of coronary artery disease**

Jin, H.Y.; Weir-McCall, J.R.; Leipsic, J.A.; Son, J.W.; Sellers, S.L.; Shao, M.; ... ; Chang, H.J.

### **Citation**

Jin, H. Y., Weir-McCall, J. R., Leipsic, J. A., Son, J. W., Sellers, S. L., Shao, M., ... Chang, H. J. (2021). The relationship between coronary calcification and the natural history of coronary artery disease. *Jacc: Cardiovascular Imaging*, 14(1), 233-242. doi:10.1016/j.jcmg.2020.08.036

Version: Publisher's Version  
License: [Leiden University Non-exclusive license](#)  
Downloaded from: <https://hdl.handle.net/1887/3279734>

**Note:** To cite this publication please use the final published version (if applicable).

ORIGINAL RESEARCH

# The Relationship Between Coronary Calcification and the Natural History of Coronary Artery Disease



Han-Young Jin, MD,<sup>a,b,\*</sup> Jonathan R. Weir-McCall, MD, PhD,<sup>c,d,\*</sup> Jonathon A. Leipsic, MD, PhD,<sup>a,e</sup> Jang-Won Son, MD, PhD,<sup>a,f</sup> Stephanie L. Sellers, PhD,<sup>a,e</sup> Michael Shao, MD,<sup>a</sup> Philipp Blanke, MD, PhD,<sup>a</sup> Amir Ahmadi, MD,<sup>e</sup> Martin Hadamitzky, MD,<sup>g</sup> Yong-Jin Kim, MD, PhD,<sup>g,h</sup> Edoardo Conte, MD,<sup>i</sup> Daniele Andreini, MD, PhD,<sup>i</sup> Gianluca Pontone, MD, PhD,<sup>i</sup> Matthew J. Budoff, MD,<sup>j</sup> Ilan Gottlieb, MD, PhD,<sup>k</sup> Byoung Kwon Lee, MD, PhD,<sup>l</sup> Eun Ju Chun, MD, PhD,<sup>m</sup> Filippo Cademartiri, MD, PhD,<sup>n</sup> Erica Maffei, MD,<sup>o</sup> Hugo Marques, MD, PhD,<sup>p</sup> Pedro de Araujo Goncalves, MD, PhD,<sup>p</sup> Sanghoon Shin, MD,<sup>q</sup> Jung Hyun Choi, MD, PhD,<sup>r</sup> Renu Virmani, MD,<sup>s</sup> Habib Samady, MD,<sup>t</sup> Peter H. Stone, MD,<sup>u</sup> Daniel S. Berman, MD,<sup>v</sup> Jagat Narula, MD, PhD,<sup>w</sup> Leslee J. Shaw, PhD,<sup>x</sup> Jeroen J. Bax, MD, PhD,<sup>y</sup> Kavitha Chinnaiyan, MD,<sup>z</sup> Gilbert Raff, MD,<sup>z</sup> Mouaz H. Al-Mallah, MD, PhD,<sup>aa</sup> Fay Y. Lin, MD, PhD,<sup>bb</sup> James K. Min, MD,<sup>bb</sup> Ji Min Sung, MD, PhD,<sup>cc,dd</sup> Sang-Eun Lee, MD, PhD,<sup>cc,dd</sup> Hyuk-Jae Chang, MD, PhD<sup>cc,dd</sup>

## ABSTRACT

**OBJECTIVES** The aim of the current study was to explore the impact of plaque calcification in terms of absolute calcified plaque volume (CPV) and in the context of its percentage of the total plaque volume at a lesion and patient level on the progression of coronary artery disease.

**BACKGROUND** Coronary artery calcification is an established marker of risk of future cardiovascular events. Despite this, plaque calcification is also considered a marker of plaque stability, and it increases in response to medical therapy.

**METHODS** This analysis included 925 patients with 2,568 lesions from the PARADIGM (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging) registry, in which patients underwent clinically indicated serial coronary computed tomography angiography. Plaque calcification was examined by using CPV and percent CPV (PCPV), calculated as  $(\text{CPV}/\text{plaque volume}) \times 100$  at a per-plaque and per-patient level (summation of all individual plaques).

**RESULTS** CPV was strongly correlated with plaque volume ( $r = 0.780$ ;  $p < 0.001$ ) at baseline and with plaque progression ( $r = 0.297$ ;  $p < 0.001$ ); however, this association was reversed after accounting for plaque volume at baseline ( $r = -0.146$ ;  $p < 0.001$ ). In contrast, PCPV was an independent predictor of a reduction in plaque volume ( $r = -0.11$ ;  $p < 0.001$ ) in univariable and multivariable linear regression analyses. Patient-level analysis showed that high CPV was associated with incident major adverse cardiac events (hazard ratio: 3.01; 95% confidence interval: 1.58 to 5.72), whereas high PCPV was inversely associated with major adverse cardiac events (hazard ratio: 0.529; 95% confidence interval: 0.229 to 0.968) in multivariable analysis.

**CONCLUSIONS** Calcified plaque is a marker for risk of adverse events and disease progression due to its strong association with the total plaque burden. When considered as a percentage of the total plaque volume, increasing PCPV is a marker of plaque stability and reduced risk at both a lesion and patient level. (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging [PARADIGM]; [NCT02803411](https://clinicaltrials.gov/ct2/show/study/NCT02803411)) (J Am Coll Cardiol Img 2021;14:233-42) © 2021 by the American College of Cardiology Foundation.

## ABBREVIATIONS AND ACRONYMS

**CAC** = coronary artery calcification

**CTA** = computed tomography angiography

**CPV** = calcified plaque volume

**HR** = hazard ratio

**HRP** = high-risk plaque

**HU** = Hounsfield units

**MACE** = major adverse cardiac event(s)

**PCPV** = percent calcified plaque volume

**PV** = plaque volume

Coronary artery calcification (CAC) is indicative of the presence of coronary atherosclerosis and is a robust marker of coronary plaque burden (1,2). Multiple studies have consistently shown that CAC is a reliable, reproducible, and independent predictor of future cardiovascular events (3,4), providing incremental information beyond traditional cardiovascular risk factors (5,6). Current guidelines endorse CAC scoring to improve cardiovascular risk assessment in asymptomatic individuals at intermediate risk to guide use of preventive therapies (7,8).

Previous studies have shown that an interval increase in coronary artery calcium is a marker of increased cardiovascular risk (9,10); however, statins induce an increase in plaque calcification despite a well-documented role in the reduction of cardiovascular events (11-13). Thus, there is an apparent paradox in our current understanding of coronary calcium in which it connotes both risk and stability, with progression portending both an increased risk of events and a response to therapy.

The aim of the current study was to examine the relationship between coronary plaque calcification, plaque volume (PV) and progression, and downstream

cardiovascular risk. The hypotheses tested were 2-fold. The first hypothesis was that at a patient level, calcified plaque would be a marker for risk and progression due to its association with total plaque burden, both calcified and noncalcified. The second hypothesis was that at a plaque lesion level, heavily calcified plaque, defined according to percentage of PV composed of calcium, would be a marker of stability and thus a lack of progression.


## METHODS

### STUDY DESIGN AND SELECTION OF PARTICIPANTS.

The PARADIGM (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging) study is an international, multicenter, observational registry prospectively collecting clinical, procedural, and follow-up data. Enrolled patients underwent clinically indicated serial coronary computed tomography angiography (CTA) with  $\geq 64$  detector rows for evaluation of coronary artery disease at a  $\geq 2$ -year interscan interval across 13 sites in 7 countries. The design of the study has been previously described in detail (14). The PARADIGM study was approved by each of the institutional review boards at the participating sites, and all participants provided written informed consent.

From the <sup>a</sup>Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada; <sup>b</sup>Division of Cardiology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea; <sup>c</sup>Royal Papworth Hospital, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; <sup>d</sup>Royal Papworth Hospital, Cambridge; <sup>e</sup>Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, British Columbia, Canada; <sup>f</sup>Yeungnam University Medical Center, Daegu, South Korea; <sup>g</sup>Department of Radiology and Nuclear Medicine, German Heart Center Munich, Munich, Germany; <sup>h</sup>Seoul National University Hospital, Seoul, South Korea; <sup>i</sup>Centro Cardiologico Monzino, IRCCS, Milan, Italy; <sup>j</sup>Department of Medicine, Lundquist Institute at Harbor UCLA Medical Center, Torrance, California; <sup>k</sup>Department of Radiology, Casa de Saude São Jose, Rio de Janeiro, Brazil; <sup>l</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea; <sup>m</sup>Seoul National University Bundang Hospital, Seoul, South Korea; <sup>n</sup>Cardiovascular Imaging Center, SDN Foundation IRCCS, Naples, Italy; <sup>o</sup>Department of Radiology, Area Vasta 1/Azienda Sanitaria Unica Regionale (ASUR) Marche, Urbino, Italy; <sup>p</sup>UNICA, Unit of Cardiovascular Imaging, Hospital da Luz, NOVA Medical School, Lisbon, Portugal; <sup>q</sup>National Health Insurance Service Ilsan Hospital, Goyang, South Korea; <sup>r</sup>Busan National University Hospital, Busan, South Korea; <sup>s</sup>Department of Pathology, CVPath Institute, Gaithersburg, Maryland; <sup>t</sup>Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; <sup>u</sup>Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; <sup>v</sup>Department of Imaging, Cedars-Sinai Medical Center, Cedars-Sinai Heart Institute, Los Angeles, California; <sup>w</sup>Icahn School of Medicine at Mount Sinai, Mount Sinai Heart, Zena and Michael A. Wiener Cardiovascular Institute, and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, New York, New York; <sup>x</sup>Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; <sup>y</sup>Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Leiden, the Netherlands; <sup>z</sup>Department of Cardiology, William Beaumont Hospital, Royal Oak, Michigan; <sup>aa</sup>King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, King Abdulaziz Cardiac Center, Ministry of National Guard, Health Affairs, Riyadh, Saudi Arabia; <sup>bb</sup>Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medical College, New York, New York; <sup>cc</sup>Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea; and the <sup>dd</sup>Yonsei-Cedars-Sinai Integrative Cardiovascular Imaging Research Centre, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea. \*Drs. Jin and Weir-McCall contributed equally to this paper and are joint first authors. Khurram Nasir, MD, served as Guest Editor for this paper.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).



Of the 2,252 patients in the PARADIGM registry, 492 were excluded due to inadequate image quality for plaque analysis. To examine the role of calcification on the natural time course of plaque, patients who underwent revascularization before baseline ( $n = 282$ ) or their follow-up ( $n = 133$ ) coronary CTA were excluded from the analysis, as were those without calcification on baseline coronary CTA ( $n = 410$ ). For the outcome analysis, an additional 51 patients were excluded due to missing data on clinical outcomes, leaving 874 patients in this analysis (Figure 1).

**DATA ACQUISITION AND IMAGE ANALYSIS.** All coronary CTA investigations were performed on  $\geq 64$ -detector CT scanners. Patient preparation, acquisition, and interpretation of CTA data were performed in accordance with Society of Cardiovascular Computed Tomography guidelines (15). All datasets including clinical information were transferred to a single core laboratory for blinded image analysis. Plaque analysis was performed by using QAngioCT Research Edition version 2.1.9.1 (Medis Medical Imaging Systems, Leiden, the Netherlands) (16).

Quantitative analysis was performed for each segment with a diameter  $\geq 2$  mm (15). These measurements included vessel length, volume, mean plaque burden, and PV at baseline and follow-up coronary CTA. Plaque composition was analyzed for all atherosclerotic plaques by using predefined Hounsfield unit (HU) thresholds: necrotic core ( $-30$  to  $30$  HU), fibro-fatty ( $30$  to  $130$  HU), fibrous ( $131$  to  $350$  HU), and calcified ( $\geq 350$  HU) plaque.

Coronary calcification was quantified in 2 ways: 1) calcified PV (CPV), which is the total volume of calcium in atherosclerotic plaque; and 2) percent CPV (PCPV), which is the degree to which the plaque is calcified and was calculated as:  $PCPV = (CPV/PV) \times 100$ .

Longitudinal analysis of changes in PV was calculated as annualized rates to account for the variability in time between baseline and follow-up coronary CTA. For longitudinal volumetric comparisons of plaque according to degree of plaque calcification, participants were split into quartiles of PCPV.

In each coronary segment with plaque, we performed further qualitative evaluation for the presence of stenosis and high-risk plaque (HRP) (17-19).

**TABLE 1 Baseline Characteristics of the Study Population (N = 925)**

Age, yrs	61.9 ± 8.95
Male	553 (59.8)
Follow-up interval of coronary CTA, yrs	2.9 (2.1-3.8)
BMI, kg/m <sup>2</sup>	25.0 (23.3-27.1)
Current smoker	176 (19.0)
Diabetes mellitus	209 (22.6)
Hypertension	518 (56.0)
Dyslipidemia	384 (41.5)
Familial history of CAD	268 (29.0)
HbA <sub>1c</sub> , %	6.0 (5.7-6.9)
Total cholesterol, mg/dl	189.9 ± 38.7
LDL cholesterol, mg/dl	114.5 ± 34.1
Serum creatinine, mg/dl	1.0 (0.8-1.1)
Medications	
Aspirin	373 (40.3)
Beta-blockers	243 (26.3)
Calcium-channel blocker	213 (23.0)
ACE inhibitor/ARB	278 (30.1)
Statins	404 (43.7)

Values are mean ± SD, median (interquartile range), or n (%).  
ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; BMI = body mass index; CAD = coronary artery disease; CTA = computed tomography angiography; HbA<sub>1c</sub> = glycosylated hemoglobin; LDL = low-density lipoprotein.

**STUDY ENDPOINTS.** The primary endpoint of the current study was to compare the annualized per-lesion change in PV according to PCPV quartile. Secondary endpoints included the association between annualized change in PV and baseline constituent plaque elements, as well as the effect of stenosis severity on the change in PV according to quartile of PCPV. The secondary clinical endpoint was the time



to major adverse cardiac events (MACE), the definition of which included myocardial infarction, cerebrovascular accident, coronary revascularization, and cardiac death.

**STATISTICAL ANALYSIS.** Continuous data are presented as mean ± SD. Differences in continuous variables between the quartile groups of PCPV were determined by 1-way analysis of variance for normal distribution and the Kruskal-Wallis test for non-normal distribution. Post hoc pairwise comparison with the Scheffé test was performed for variables for which there was a significant difference between groups. Categorical variables were expressed as frequencies and percentages, which were compared by using the Pearson chi-square test between the 4 PCPV quartiles. The correlation of CPV with PV was analyzed by using Spearman's correlation test, and partial correlation analysis was used to analyze the association of CPV and annualized change in PV, accounting for baseline PV. Univariable and multivariable linear regression models were used to identify variables associated with the annualized change in PV at a per-lesion level without cluster adjustment. Plaque volumes were log transformed for linear regression due to non-normal distribution of the residuals. The association of calcified plaque with clinical outcomes was investigated with the Cox proportional hazards model using univariable and stepwise multivariable analyses. The stepwise multivariable analyses included all clinical risk factors, variables of CTA, and statin use. For this analysis, we used values of CPV and PCPV in the patient-level data, which

**TABLE 2 Coronary Plaque Characteristics on Baseline Coronary CTA According to Quartile of PCPV**

	PCPV, Quartile				p Value*	Total Lesions (N = 2,568)
	1 (n = 642)	2 (n = 643)	3 (n = 641)	4 (n = 643)		
PCPV range, %	0.01-17.1	17.2-40.0	40.1-63.5	63.6-99.6	<0.001	41.2 ± 27.4
Lesion length, mm	23.2 ± 13.8	23.6 ± 15.8	22.8 ± 15.6	21.2 ± 14.9	0.027	22.7 ± 14.8
Total PV, mm <sup>3</sup>	54.2 ± 77.9	52.4 ± 83.8	47.0 ± 75.0	40.5 ± 70.9	0.007	48.5 ± 77.2
Fibrous PV, mm <sup>3</sup>	30.6 ± 41.0	29.0 ± 45.3	19.9 ± 31.0	8.9 ± 15.8	<0.001	22.1 ± 36.2
Fibro-fatty PV, mm <sup>3</sup>	17.8 ± 30.1	8.0 ± 16.0	2.7 ± 6.9	0.6 ± 2.4	<0.001	7.3 ± 18.7
Calcified PV, mm <sup>3</sup>	3.7 ± 7.5	14.8 ± 25.1	24.3 ± 38.7	31.1 ± 54.8	<0.001	18.5 ± 37.4
Necrotic core volume, mm <sup>3</sup>	2.1 ± 6.0	0.6 ± 2.0	0.2 ± 0.9	0.04 ± 0.3	<0.001	0.75 ± 3.3
Plaque burden, mm <sup>3</sup>	39.5 ± 17.4	39.3 ± 16.6	40.7 ± 17.6	42.9 ± 16.6	<0.001	40.6 ± 17.1
Area stenosis, %	29.8 ± 18.8	31.7 ± 19.2	32.5 ± 19.4	34.6 ± 19.9	<0.001	32.2 ± 19.4
Low-attenuation plaque	135 (21.0)	36 (8.4)	10 (3.1)	2 (0.3)	<0.001	211 (8.2)
Spotty calcium	139 (21.7)	111 (17.3)	48 (7.5)	18 (2.8)	<0.001	316 (12.3)
Positive remodeling	487 (75.9)	435 (67.7)	449 (70.0)	449 (69.9)	0.01	1,820 (70.9)
Napkin-ring sign	3 (0.5)	4 (0.6)	0 (0.0)	0 (0.0)	0.06	7 (0.3)
High-risk plaque	250 (9.7)	82 (12.0)	33 (1.3)	4 (0.2)	<0.001	369 (14.4)

Values are range, or mean ± SD, or n (%). \*The p value is for the overall comparison among the groups by analysis of variance or Pearson chi-square test.  
CTA = coronary computed tomography angiography; PCPV = percent calcified plaque volume; PV = plaque volume.



**TABLE 3 Variables Associated With the Change of PV in Linear Regression Model**

	Univariable		Multivariable	
	Correlation Coefficient	p Value	Unstandardized Coefficient (95% CI)	p Value
PCPV*	-0.08	<0.001	-0.82 (-1.10 to -0.55)	<0.001
Calcified PV*	0.37	<0.001	0.81 (0.55 to 1.07)	<0.001
Total PV*	0.42	<0.001	-†	
Necrotic core volume*	0.23	<0.001	0.02 (-0.05 to 0.08)	0.64
Mean plaque burden*	0.42	<0.001	0.53 (0.22 to 0.85)	0.001
Lesion length	0.52	<0.001	0.024 (-0.13 to 0.61)	0.20
Area stenosis	0.14	<0.001	0.01 (-0.10 to 0.13)	0.82
Any HRP	0.19	<0.001	0.04 (-0.17 to 0.24)	0.73
Spotty calcification	0.18	<0.001		
Low attenuation plaque	0.19	<0.001		
Positive remodeling	0.13	<0.001		
Napkin-ring sign	0.05	0.008		

\*Log-transformed for analysis. †Total PV was excluded in the multivariable model due to strong correlation with calcified plaque volume.  
CI = confidence interval; HRP = high-risk plaque; other abbreviations as in Table 2.

were classified into 2 groups by the median value of each of these.

The Cox model was used to estimate the risk of a given variable as expressed by a hazard ratio (HR) with corresponding 95% confidence interval (CI). Survival curves were generated by using the Kaplan-Meier method, and the difference between curves was assessed by using the log-rank test. A p value  $\leq$  0.05 was considered statistically significant. All statistical analysis was performed by using SPSS version 22 (IBM SPSS Statistics, IBM Corporation, Armonk, New York) and SAS 9.2 (SAS Institute, Inc., Cary, North Carolina) software.

## RESULTS

**STUDY POPULATION.** Of the 2,252 patients, 925 (mean age  $61.9 \pm 8.95$  years; 59.8% male) with 2,568 lesions were included in the final analysis. Clinical and laboratory characteristics of this cohort are shown in Table 1.

**CHANGE OF ATHEROSCLEROTIC PV AND CORONARY ARTERY CALCIFICATION.** A lesion-level analysis was performed for a total of 2,586 lesions. For volumetric comparisons of plaque, participants were classified into 4 groups according to quartile of PCPV value in baseline coronary CTA (Table 2). Lesions with the highest PCPV (fourth quartile) were shorter lesions, with a lower volume of plaque, greater severity of stenosis, higher plaque burden, and less frequent HRP compared with lower PCPV (all;  $p < 0.05$ ). Annualized change in PV was greatest in lesions with the lowest PCPV (first quartile) and decreased monotonically across the 4 quartiles of PCPV, which


was statistically significant in an intergroup comparison (all;  $p < 0.001$ ) (Figure 2A). The same trend was observed in the volume of each of the plaque components, which were statistically significant in an intergroup comparison (all;  $p < 0.001$ ) (Figures 2B to 2D). The rate of newly detected HRP on follow-up CT imaging, similarly, was highest in the lowest PCPV quartile and decreased across the 4 quartiles with increasing PCPV (Figure 2F). Change in CPV was smallest in the first quartile, but change was greatest in the second quartile and decreased across the third and fourth quartiles (Figure 2E).

These observations were robust when analyzed according to the severity of stenosis, as well as baseline or interval statin prescription. Regardless of stenosis severity, there were significant differences in annualized change in PV between PCPV quartile groups (Figure 3, Supplemental Figure 1). Statin therapy either at baseline or interval prescription between the coronary CTAs was associated with a greater increase in the PCPV than those never treated with a statin (never statin  $3.5 \pm 7.7\%$  per year; baseline/interval statin  $4.3 \pm 6.9\%$  per year;  $p = 0.017$ ).

**CORRELATION BETWEEN CORONARY CALCIFICATION, PV, AND ITS CHANGE.** The CPV was strongly correlated with PV at the baseline CT scan ( $r = 0.780$ ;  $p < 0.001$ ). On univariable linear regression analysis, factors significantly and positively associated with change in PV were baseline CPV, lesion length, necrotic core volume, mean plaque burden, area stenosis, and HRP (all;  $p < 0.001$ ). In contradistinction, PCPV was significantly and inversely associated with change in PV ( $r = -0.08$ ;  $p < 0.001$ ) (3). A partial correlation model was also used to account for baseline PV due to a strong association between CPV and PV, which showed that CPV was significantly and inversely correlated with change in PV after adjustment for PV at baseline coronary CTA ( $r = -0.146$ ;  $p < 0.001$ ). After adjustment, PCPV was independently and inversely associated with change in total PV on the multivariable linear regression analysis (B: -0.82; 95% CI: -1.10 to -0.55;  $p < 0.001$ ), whereas CPV remained positively associated with change in PV (B: 0.81; 95% CI: 0.55 to 1.07;  $p < 0.001$ ) (Table 3).

**CORONARY CALCIFICATION AND CLINICAL OUTCOMES.** A total of 874 patients (mean age  $62.1 \pm 9.1$  years; 58.2% male) were included in the analyses of clinical outcomes (Supplemental Table 1). Over a median follow-up of 4.3 years (interquartile range 2.6 to 6 years), 110 patients (12.6%) experienced MACE, which was mostly driven by revascularization ( $n = 106$  [12.1%]). Patients with high PCPV had a significantly

**CENTRAL ILLUSTRATION** Plaque Progression and Major Adverse Cardiac Events According to Percent Calcified Plaque Volume and Calcified Plaque Volume



Jin, H.-Y. et al. J Am Coll Cardiol Img. 2021;14(1):233-42.

Those with higher percent calcified plaque volume (PCPV) had greater rates of plaque progression (**top left**) and higher rates of major adverse cardiac event(s) (MACE) (**top right**). The graphic summarizes the key characteristics of plaques with low and high PCPV.

lower incidence of MACE (14.6% vs. 9.4%; p = 0.022) and revascularization (14.3% vs 8.8%; p = 0.016) than those with low PCPV (Supplemental Table 2). When categorizing patients using PCPV and CPV, Kaplan-Meier analysis showed that the survival rate free from MACE was highest in patients with a high PCPV and low CPV (log rank test; p < 0.001) (Central Illustration).

On multivariable Cox proportional analysis, high PCPV was significantly and inversely associated with MACE (HR: 0.53; 95% CI: 0.29 to 0.97; p = 0.04), whereas high CPV was associated with increased risk

of MACE (HR: 3.01; 95% CI: 1.58 to 5.72; p = 0.001) (Table 4).

**DISCUSSION**

In the current study from a large prospective multinational registry of patients undergoing serial coronary CTA, we found that calcified plaque is a marker of risk and disease progression due to its strong association with the total plaque burden. When considered as a percentage of the total PV, increasing calcification is a marker of plaque stability and



**TABLE 4 Predicting Factors for the Composite of Major Cardiovascular Events**

	Univariable Analysis			
	Unadjusted		Adjusted*	
	HR (95% CI)	p Value	HR (95% CI)	p Value
High percent calcified PV	0.57 (0.35-0.95)	0.029	0.56 (0.33-0.94)	0.029
High calcified PV	2.60 (1.61-4.20)	<0.001	2.65 (1.60-4.39)	<0.001
High total PV	2.14 (1.34-3.40)	0.001	2.09 (1.29-3.40)	0.003
High mean plaque burden	2.74 (1.69-4.46)	<0.001	2.72 (1.64-4.52)	<0.001
High necrotic core volume	3.03 (1.84-4.99)	<0.001	3.19 (1.89-5.39)	<0.001
	Multivariable Analysis†			
	HR (95% CI)		p Value	
High percent calcified PV	0.53 (0.29-0.97)		0.039	
High calcified PV	3.01 (1.58-5.72)		0.001	
High total PV	2.04 (0.96-4.30)		0.06	
High mean plaque burden	1.63 (0.79-3.39)		0.19	
High necrotic core volume	2.13 (1.12-4.07)		0.022	
Age >70 yrs	1.15 (0.69-1.90)		0.56	
Male	1.08 (0.65-1.78)		0.34	
Smoking	1.09 (0.67-1.78)		0.74	
Diabetes mellitus	1.27 (0.79-2.06)		0.39	
Hypertension	1.31 (0.79-2.19)		0.13	
Dyslipidemia	0.82 (0.49-1.34)		0.89	
Familial history of CAD	0.99 (0.59-1.70)		0.99	
Statin use	0.53 (0.30-0.93)		0.028	

High volume of plaque and its constituent elements were defined as above median value of each variable in turn. \*Models were adjusted for the following covariates: age, sex, smoking, diabetes, hypertension, familial history of CAD, and dyslipidemia. †All clinical risk factors, variables of coronary CTA, and statin use were applied together in a multivariate Cox proportional hazards regression.

HR = hazard ratio; other abbreviations as in [Tables 1 and 3](#).

reduced risk at both a lesion and patient level. The current findings highlight that a more nuanced approach is required to use calcified plaque change in serial imaging studies as a risk marker. PCPV, which captures the interplay between calcified plaque and total PV, may be considered a marker of increasing plaque stability and should be additionally considered when assessing patient risk and treatment response.

#### INSIGHTS INTO THE ASSOCIATION BETWEEN CORONARY CALCIFICATION AND THE NATURAL HISTORY OF CORONARY ARTERY DISEASE.

Extensive investigation has shown that CAC is an independent predictor of adverse events, with a significant incremental prognostic value over traditional risk stratification (3-6,20). To date, the majority of cardiac CT studies examining the role of coronary calcium in predicting coronary artery disease have used simple quantification and scoring of calcification without considering noncalcified plaque burden. Previous studies with intravascular ultrasound and coronary CTA have shown that calcified plaques are more resistant to change and progression of PV

(21,22), although these studies used a qualitative or semi-quantitative method to evaluate the coronary calcification and were limited to short coronary segment assessment.

In the current study, we analyzed serial coronary CTA from a large prospective registry with a quantitative methodology, incorporating both the standard volume measurement of plaque calcification but also the novel metric of PCPV to contextualize CPV in terms of the plaque burden in its entirety (**Central Illustration**). The present data provide novel observations that PCPV was inversely related to change in PV and cardiovascular events, whereas CPV was positively associated with clinical outcomes and was more predictive when adjusted for PCPV. These findings are consistent with previous studies that coronary calcification is an independent risk factor for future adverse events, reflecting coronary atherosclerotic burden (3,4), with this plaque burden in turn positively associated with progression (22,23). Heavily calcified plaque was found to be associated with a lower interval change in PV and improved MACE-free survival in agreement with a study by Rosendaal et al. (24) (i.e., that hyperdense plaque [ $>1,000$  HU] is associated with a lower risk of subsequent acute coronary syndromes).

Several studies have shown that the calcium density on coronary artery calcium scoring studies is inversely related to future events (25,26). It may be that calcium density is a marker of the percentage of calcified plaque, as these observations on plaque density are congruent with our observations on PCPV. However, the calcium score uses only the single pixel with the highest attenuation to define plaque density, which may not distinguish a nodule of dense calcification sitting in a very large necrotic plaque from a dense isolated nodule of calcification. Further examination of coronary artery plaque calcification, density, PCPV, and risk is required to better understand how these factors relate.

#### CORONARY ARTERY CALCIFICATION AND MEDICAL THERAPY.

Studies investigating the effect of statins on plaque composition show that statins promote coronary calcification, with progression in the CAC score (11-13). This finding, however, seems contradictory as CAC progression has been associated with poorer clinical outcome (9,10,27). Because statins affect both the volume of calcified and noncalcified plaque (11,12), measuring coronary calcification in isolation is limited in its assessment of the effects of statins. In this regard, PCPV may better reflect the beneficial effect of preventative therapies on coronary plaque. High-intensity statins increase the

calcium volume but not total PV, which results in a pronounced increase in PCPV. The fact that higher PCPV is in turn predictive of lower rates of plaque progression and cardiovascular events aligns with the expected clinical outcomes of this preventative therapy. These findings suggest that PCPV should be a factor when considering risk stratification by coronary calcium quantification.

**STUDY LIMITATIONS.** Calcium scoring was not routinely performed as part of the PARADIGM study, and thus as a result, the extent to which the current findings affect the translation of coronary artery calcium scoring cannot be examined. The current study analyzed those with clinically indicated serial coronary CTA, and thus the results need to be re-examined in a primary prevention cohort to determine if they are translatable into this cohort. We also excluded patients who underwent revascularization between their baseline and follow-up CT scan as this could physically and hemodynamically affect the natural course of lesions. Therefore, there is a possibility that the most severe and vulnerable lesions were excluded in the analysis.

## CONCLUSIONS

Calcified plaque is a marker of risk and disease progression due to its strong association with the total plaque burden. When considered as a percentage of the total PV, increasing calcification is a marker of plaque stability and reduced risk at both a lesion and patient level. These findings suggest that PCPV should be considered when proposing risk stratification by coronary calcium quantification

## AUTHOR DISCLOSURES

This study was supported by the Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT and Future Planning (grant 2012027176) and funded in part by a generous gift from the Dalio Institute of Cardiovascular Imaging and the Michael Wolk Foundation. This work was supported by a grant from Research year of Inje University in 20170038. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Dr. Chang has received funding from the Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning (grant 2012027176). Dr. Min has received funding from the National Institutes of Health (grants R01 HL111141, R01 HL115150, R01 118019,

and U01 HL 105907), the Qatar National Priorities Research Program (grant 09-370-3-089), and GE Healthcare; has served as a consultant to HeartFlow; serves on the scientific advisory board of Arineta; and has an equity interest in MDDX. Dr. Bax has received unrestricted research grants from Biotronik, Medtronic, Boston Scientific, and Edwards Lifesciences. Dr. Chun has received funding from a National Research Foundation grant funded by the South Korea government (MEST) (NRF-2015R1D1A1A01059717). Dr. Leipsic serves as a consultant and has stock options in HeartFlow and Circle Cardiovascular Imaging; and receives speaking fees from GE Healthcare. Dr. Budoff has received grant support from the National Institutes of Health and GE Healthcare. Dr. Samady has received grant support from Phillips/Volcano and St. Jude Abbott/Medtronic/Gilead. Dr. Andreini is on the Speakers Bureau for GE Healthcare; and receives grant support from GE Healthcare and Bracco. Dr. Pontone has received institutional research grants from GE Healthcare, HeartFlow, Medtronic, Bracco, and Bayer. Dr. Berman has received software royalties from Cedars-Sinai. Dr. Virmani has received institutional research support from 480 Biomedical, Abbott Vascular, ART, BioSensors International, Biotronik, Boston Scientific, CeloNova, Claret Medical, Cook Medical, Cordis, Edwards Lifesciences, Medtronic, MicroVention, OrbusNeich, ReCor, SINO Medical Technology, Spectranetics, Surmodics, Terumo Corporation, W.L. Gore, and Xeltis; has received honoraria from 480 Biomedical, Abbott Vascular, Boston Scientific, Cook Medical, Lutonix, Medtronic, Terumo Corporation, and W.L. Gore; and is a consultant for 480 Biomedical, Abbott Vascular, Medtronic, and W.L. Gore. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

**ADDRESS FOR CORRESPONDENCE:** Dr. Jonathon A. Leipsic, Department of Radiology, St. Paul's Hospital, 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada. E-mail: [jleipsic@providencehealth.bc.ca](mailto:jleipsic@providencehealth.bc.ca).

## PERSPECTIVES

**COMPETENCY IN MEDICAL KNOWLEDGE:** Coronary artery calcification is a marker of cardiovascular risk. This is due to its strong association with total plaque burden. However, patients may have a low calcium burden with a high plaque burden or a high calcium burden with a low noncalcified plaque burden. When considered as a percentage of total plaque, a high percentage of calcified plaque is associated with lower risk of plaque progression and lower risk of MACE.

**TRANSLATIONAL OUTLOOK:** Preventative treatments such as statins increase calcified plaque burden. Given the findings of the current study, the percent CPV needs to be assessed in prospective interventional trials to determine if it better captures treatment response and reduction of risk.

## REFERENCES

1. Rumberger JA, Simons DB, Fitzpatrick LA, Shedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. *Circulation* 1995;92:2157-62.
2. Sangiorgi G, Rumberger JA, Severson A, et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalsifying methodology. *J Am Coll Cardiol* 1998;31:126-33.

3. Hermann DM, Gronewold J, Lehmann N, et al. Heinz Nixdorf Recall Study Investigative Group. Coronary artery calcification is an independent stroke predictor in the general population. *Stroke* 2013;44:1008-13.
4. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. *N Engl J Med* 2008;358:1336-45.
5. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. *JAMA* 2004;291:210-5.
6. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. *JAMA* 2012;308:788-95.
7. Goff DC Jr., Lloyd-Jones DM, Bennett G, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014;63:2935-59.
8. Piepoli MF, Hoes AW, Agewall S, et al., ESC Scientific Document Group. 2016 European Guidelines on Cardiovascular Disease Prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J* 2016;37:2315-81.
9. Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. *Arterioscler Thromb Vasc Biol* 2004;24:1272-7.
10. Budoff MJ, Hokanson JE, Nasir K, et al. Progression of coronary artery calcium predicts all-cause mortality. *J Am Coll Cardiol Img* 2010;3:1229-36.
11. Hiro T, Kimura T, Morimoto T, et al., JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] study). *J Am Coll Cardiol* 2009;54:293-302.
12. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. *N Engl J Med* 2011;365:2078-87.
13. Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. *J Am Coll Cardiol* 2015;65:1273-82.
14. Lee SE, Chang HJ, Rizvi A, et al. Rationale and design of the progression of Atherosclerotic Plaque Determined by computed Tomographic angiography IMaging (PARADIGM) registry: a comprehensive exploration of plaque progression and its impact on clinical outcomes from a multicenter serial coronary computed tomographic angiography study. *Am Heart J* 2016;182:72-9.
15. Leipsic J, Abbara S, Achenbach S, et al. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. *J Cardiovasc Comput Tomogr* 2014;8:342-58.
16. Boogers MJ, Broersen A, van Velzen JE, et al. Automated quantification of coronary plaque with computed tomography: comparison with intravascular ultrasound using a dedicated registration algorithm for fusion-based quantification. *Eur Heart J* 2012;33:1007-16.
17. Otsuka K, Fukuda S, Tanaka A, et al. Napkin-ring sign on coronary CT angiography for the prediction of acute coronary syndrome. *J Am Coll Cardiol Img* 2013;6:448-57.
18. Puchner SB, Liu T, Mayrhofer T, et al. High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial. *J Am Coll Cardiol* 2014;64:684-92.
19. Motoyama S, Ito H, Sarai M, et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. *J Am Coll Cardiol* 2015;66:337-46.
20. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. *J Am Coll Cardiol* 2005;46:158-65.
21. Nicholls SJ, Tuzcu EM, Wolski K, et al. Coronary artery calcification and changes in atheroma burden in response to established medical therapies. *J Am Coll Cardiol* 2007;49:263-70.
22. Lehman SJ, Schlett CL, Bamberg F, et al. Assessment of coronary plaque progression in coronary computed tomography angiography using a semiquantitative score. *J Am Coll Cardiol Img* 2009;2:1262-70.
23. Stone PH, Saito S, Takahashi S, et al., PREDICTION Investigators. Prediction of progression of coronary artery disease and clinical outcomes using vascular profiling of endothelial shear stress and arterial plaque characteristics: the PREDICTION study. *Circulation* 2012;126:172-81.
24. van Rosendaal AR, Narula J, Lin FY, et al. Association of high-density calcified 1K plaque with risk of acute coronary syndrome. *JAMA Cardiol* 2020;5:282-90.
25. Criqui MH, Denenberg JO, Ix JH, et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. *JAMA* 2014;311:271-8.
26. Criqui MH, Knox JB, Denenberg JO, et al. Coronary artery calcium volume and density: potential interactions and overall predictive value: The Multi-Ethnic Study of Atherosclerosis. *J Am Coll Cardiol Img* 2017;10:845-54.
27. Raggi P, Cooil B, Shaw LJ, et al. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. *Am J Cardiol* 2003;92:827-9.

---

**KEY WORDS** atherosclerosis, coronary artery calcium, coronary artery disease, coronary computed tomography angiography, statins

---

**APPENDIX** For supplemental tables and a figure, please see the online version of this paper.